Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis
Clinical & Experimental Metastasis · 2025-02 · 42 (1)
DOI: 10.1007/s10585-024-10322-1 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical & Experimental Metastasis, online erschienen am 16.12.2024. Verfasst von Alessandro Rizzo und 7 weiteren Autor:innen. Beteiligte Einrichtung: S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari, 70124, Italy. rizzo.ale…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Studies conducted in the last few years have suggested a connection between clinical outcomes and the time of immune checkpoint inhibitors (ICIs) infusion. However, few data are available regarding the differences between early and late time-of-day (ToD) administration in metastatic renal cell carcinoma (mRCC) patients receiving immunotherapy and immune-based combinations. In this meta-analysis, we aimed to fully investigate the influence of timing of administration on the efficacy of mRCC immunotherapy, by comparing early ToD versus late ToD dosing in this setting. The present systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). Overall Survival (OS) was measured as Hazard Ratios (HRs) and 95% confidence intervals (CIs). Our search resulted in the identification of 1429 potentially relevant reports, which were subsequently restricted to four following independent evaluation of three authors. The pooled HR for OS in RCC patients receiving early ToD versus late ToD dosing was 0.62 (95% Confidence Interval, 0.50-0.72; p < 0.001). According to our findings, a statistically significant improvement in terms of OS for mRCC patients receiving early ToD administration compared with late ToD dosing was observed, with a reduction of death by 38%. Well-designed, randomized clinical and translational trials are required to clarify this issue and to establish recommendations for personalized treatments according to ToD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari, 70124, Italy. rizzo.alessandro179@gmail.com.
- Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil.
- Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil.
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
- S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari, 70124, Italy.
Zitieren
APA
Rizzo, A., Monteiro, F. S. M., Mollica, V., Soares, A., Brunetti, O., Ricci, A. D., Massari, F., & Santoni, M. (2025). Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis. Clinical & Experimental Metastasis, 42(1). https://doi.org/10.1007/s10585-024-10322-1
Vancouver
Rizzo A, Monteiro FSM, Mollica V, Soares A, Brunetti O, Ricci AD, et al. Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis. Clinical & Experimental Metastasis. 2025;42(1). doi:10.1007/s10585-024-10322-1
BibTeX
@article{Rizzo2025,
author = {Rizzo, Alessandro and Monteiro, Fernando Sabino Marques and Mollica, Veronica and Soares, Andrey and Brunetti, Oronzo and Ricci, Angela Dalia and Massari, Francesco and Santoni, Matteo},
title = {Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis},
journal = {Clinical & Experimental Metastasis},
year = {2025},
volume = {42},
number = {1},
doi = {10.1007/s10585-024-10322-1}
}
EUVIMED